Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude sur le guselkumab chez des participants pédiatriques atteints de la maladie de Crohn modérément à sévèrement active (MACARONI-23)

2 novembre 2026 mis à jour par: Janssen Research & Development, LLC

Une étude de phase 3, multicentrique, randomisée, plate-forme de l'inhibition de p19 de la voie IL-23 pour établir l'efficacité dans la maladie de Crohn pédiatrique

The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Type d'étude

Interventionnel

Inscription (Estimé)

120

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Nedlands, Australie, 6009
        • Recrutement
        • Perth Children's Hospital
      • South Brisbane, Australie, 4101
        • Recrutement
        • Mater Hospital Brisbane
      • Westmead, Australie, 2145
        • Recrutement
        • The Children's Hospital at Westmead
      • Brussels, Belgique, 1090
        • Recrutement
        • Universitair Ziekenhuis Brussel
      • Brussels, Belgique, 1200
        • Recrutement
        • Cliniques Universitaires Saint Luc
      • Ghent, Belgique, 9000
        • Recrutement
        • Universitair Ziekenhuis Gent
      • Leuven, Belgique, 3000
        • Recrutement
        • UZ Leuven
      • Campinas, Brésil, 13060-904
        • Recrutement
        • Sociedade Campineira de Educacao e Instrucao Hospital e Maternidade Celso Pierro
      • Curitiba, Brésil, 80250-060
        • Recrutement
        • Associacao Hospitalar de Protecao a Infancia Dr. Raul Carneiro
      • Goiânia, Brésil, 74605-020
        • Recrutement
        • Universidade Federal de Goias - Hospital das Clinicas da UFG
      • Porto Alegre, Brésil, 90035-074
        • Recrutement
        • Irmandade Santa Casa de Misericordia de Porto Alegre
      • Porto Alegre, Brésil, 90035-007
        • Recrutement
        • Hospital De Clinicas De Porto Alegre
      • Vitória, Brésil, 29040-091
        • Recrutement
        • Centro de Ciencias e Saude da Universidade Federal do Espirito Santo-Nucleo de Doencas Infecciosas
      • Votuporanga, Brésil, 100000
        • Recrutement
        • INTEGRAL Pesquisa e Ensino
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3K 6R8
        • Recrutement
        • Iwk Health Centre
    • Ontario
      • London, Ontario, Canada, N6A 5W9
        • Recrutement
        • London Health Sciences Centre Victoria Hospital
      • Toronto, Ontario, Canada, M5G 1X8
        • Recrutement
        • Hospital For Sick Children
      • Busan, Corée du Sud, 48108
        • Recrutement
        • Inje University Haeundae Paik Hospital
      • Daegu, Corée du Sud, 41404
        • Recrutement
        • Kyungpook National University Chilgok Hospital
      • Seoul, Corée du Sud, 03080
        • Recrutement
        • Seoul National University Hospital
      • Seoul, Corée du Sud, 06351
        • Recrutement
        • Samsung Medical Center
      • Seoul, Corée du Sud, 120-752
        • Recrutement
        • Severance Hospital Yonsei University Health System
      • Córdoba, Espagne, 14004
        • Recrutement
        • Hosp Reina Sofia
      • Sabadell, Espagne, 8208
        • Recrutement
        • Corporacio Sanitari Parc Tauli
      • Valencia, Espagne, 46026
        • Recrutement
        • Hosp. Univ. I Politecni La Fe
      • Amiens, France, 80054
        • Recrutement
        • CHU Amiens-Hopital Nord
      • Lille, France, 59037
        • Recrutement
        • Hôpital Jeanne de FLANDRE, CHRU LILLE
      • Paris, France, 75019
        • Recrutement
        • Hôpital Robert Debré
      • Paris, France, 75015
        • Recrutement
        • Hôpital Necker - Enfants Malades
      • Beersheba, Israël, 84101
        • Recrutement
        • Soroka University Medical Center
      • Be’er Ya‘aqov, Israël, 70300
        • Recrutement
        • Shamir Medical Center Assaf Harofeh
      • Jerusalem, Israël, 9103102
        • Recrutement
        • Shaare Zedek Medical Center
      • Jerusalem, Israël, 9124001
        • Recrutement
        • Hadassah Medical Center
      • Petah Tikva, Israël, 4920235
        • Recrutement
        • Schneider Children's Medical Center
      • Rehovot, Israël, 761001
        • Recrutement
        • Kaplan Medical Center
      • Alessandria, Italie, 15121
        • Recrutement
        • A.O. Santi Antonio e Biagio e Cesare Arrigo
      • Bergamo, Italie, 24127
        • Recrutement
        • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
      • Bologna, Italie, 40124
        • Recrutement
        • Ospedale Bellaria, U.O.Cardiologia Az. USL di Bologna
      • Florence, Italie, 50139
        • Recrutement
        • Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
      • Milan, Italie, 20154
        • Recrutement
        • Azienda Socio Sanitaria Territoriale Fatebenefratelli Presidio Ospedale dei Bambini Vittore Buzzi
      • Roma, Italie, 161
        • Recrutement
        • AOU Policlinico Umberto I
      • Hirosaki, Japon, 036-8563
        • Recrutement
        • Hirosaki University Hospital
      • Kagoshima, Japon, 890-8544
        • Recrutement
        • Kagoshima University Hospital
      • Kashiwa-shi, Japon, 277-0871
        • Recrutement
        • Tsujinaka Hospital Kashiwanoha
      • Kobe, Japon, 650 0017
        • Recrutement
        • Kobe University Hospital
      • Saga, Japon, 849-8501
        • Recrutement
        • Saga University Hospital
      • Sendai, Japon, 989-3126
        • Recrutement
        • Miyagi Childrens Hospital
      • Setagaya Ku, Japon, 157 8535
        • Recrutement
        • National Center for Child Health and Development
      • Tokyo, Japon, 113-8431
        • Recrutement
        • Juntendo University Hospital
      • Tsu, Japon, 514 8507
        • Recrutement
        • Mie University Hospital
      • Ube, Japon, 755-8505
        • Recrutement
        • Yamaguchi University Hospital
      • Yokohama, Japon, 232-0024
        • Recrutement
        • Yokohama City University Medical Center
      • Yokohama, Japon, 230-8765
        • Recrutement
        • Saiseikai Yokohamashi Tobu Hospital
      • Vienna, L'Autriche, 1090
        • Recrutement
        • AKH - Medizinische Universitat Wien
      • Braga, Le Portugal, 4710-243
        • Recrutement
        • Hospital de Braga
      • Lisbon, Le Portugal, 1649-035
        • Recrutement
        • Centro Hospitalar de Lisboa Norte Hospital Santa Maria
      • Porto, Le Portugal, 4200-319
        • Recrutement
        • Centro Hospitalar de Sao Joao E.P.E.
      • Nordbyhagen, Norvège, 1474
        • Recrutement
        • Akershus Universitetssykehus HF
      • Oslo, Norvège, 424
        • Recrutement
        • Oslo University Hospital
      • Tromsø, Norvège, 9038
        • Recrutement
        • Universitetssykehuset Nord-Norge HF
      • Trondheim, Norvège, 7030
        • Recrutement
        • St. Olavs Hospital
      • Rotterdam, Pays-Bas, 3015 GD
        • Recrutement
        • Erasmus Medisch Centrum
      • Rzeszów, Pologne, 35-302
        • Recrutement
        • Korczowski Bartosz Gabinet Lekarski
      • Warsaw, Pologne, 04 501
        • Recrutement
        • WIP Warsaw IBD Point Profesor Kierkus
      • Warsaw, Pologne, 04 730
        • Recrutement
        • Instytut Pomnik Centrum Zdrowia
      • Glasgow, Royaume-Uni, G51 4TF
        • Recrutement
        • Royal Hospital for Sick Children
      • London, Royaume-Uni, WC1N 3JH
        • Recrutement
        • Great Ormond Street Hospital
      • Manchester, Royaume-Uni, M13 9WL
        • Recrutement
        • Royal Manchester Children's Hospital
      • Manchester, Royaume-Uni, M13 9WL
        • Recrutement
        • Nowgen Centre, Research and Innovation
      • Oxford, Royaume-Uni, OX3 9DU
        • Recrutement
        • John Radcliffe Hospital
      • Sheffield, Royaume-Uni, S10 2TH
        • Recrutement
        • Sheffield Children's Hospital
    • California
      • Los Angeles, California, États-Unis, 90048
        • Recrutement
        • Cedars Sinai Medical Center
    • Connecticut
      • Hartford, Connecticut, États-Unis, 06106
        • Recrutement
        • Connecticut Children's Medical Center
    • Georgia
      • Atlanta, Georgia, États-Unis, 30322
        • Recrutement
        • Emory University
      • Atlanta, Georgia, États-Unis, 30342
        • Recrutement
        • Children's Center for Digestive Health Care
    • Indiana
      • Indianapolis, Indiana, États-Unis, 46202-5225
        • Recrutement
        • Riley Hospital for Children
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02115
        • Recrutement
        • Boston Childrens Hospital
    • New Jersey
      • Morristown, New Jersey, États-Unis, 07960
        • Recrutement
        • Goryeb Children's Hospital
    • New York
      • New York, New York, États-Unis, 10029
        • Recrutement
        • Icahn School of Medicine at Mount Sinai
      • New York, New York, États-Unis, 10032
        • Recrutement
        • Columbia University Medical Center
      • New York, New York, États-Unis, 10021-5663
        • Recrutement
        • Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center
    • Ohio
      • Dayton, Ohio, États-Unis, 45404
        • Recrutement
        • The Children's Medical Center of Dayton
    • Pennsylvania
      • Philadelphia, Pennsylvania, États-Unis, 19104
        • Recrutement
        • Children's Hospital of Philadelphia
    • Texas
      • Fort Worth, Texas, États-Unis, 76104
        • Recrutement
        • Cook Childrens Medical Center
    • Vermont
      • Colchester, Vermont, États-Unis, 05446
        • Recrutement
        • University of Vermont Medical Center

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

2 ans à 17 ans (Enfant)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Participants must have a diagnosis of Crohn's Disease (CD) or fistulizing CD, with active colitis, ileitis, or ileocolitis, confirmed at any time in the past by clinical, endoscopic, and histologic criteria.
  • Participants must have moderately to severely active CD (as defined by a baseline Pediatric Crohn's Disease Activity Index [PCDAI] score greater than or equal to [>=] 30)
  • Participants must have endoscopy with evidence of active CD defined as Simple Endoscopic Score for Crohn's Disease (SES-CD) score greater than or equal to (>=) 6 (or >=4 for participants with isolated ileal disease) within 1 month of receiving study intervention at Week 0
  • Participants must have a history of inadequate response, loss of response, or intolerance to immunomodulators (6-MP, AZA, or MTX), oral or IV corticosteroids, or biologic therapy/JAK inhibitor therapy; OR have a history of corticosteroid dependence; OR have a history of inadequate response to exclusive enteral nutrition (EEN)

Exclusion Criteria:

  • Participants has complications of CD such as symptomatic strictures or stenosis, short gut syndrome, or any other manifestation that might be anticipated to require surgery.
  • Participants must not have an abscess
  • Participants must not have any kind of bowel resection within 26 weeks or any other intra-abdominal surgery within 12 weeks of baseline

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Open-label induction phase: Guselkumab Intravenously (IV)

Participants will receive guselkumab dose IV based on their body weight during the 12-week open-label induction phase.

Guselkumab will be administered subcutaneously.

Autres noms:
  • CNTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Autres noms:
  • CNTO1959
  • TREMFYA
Expérimental: Open-label induction phase: Guselkumab Subcutaneously (SC)

Participants will receive guselkumab dose SC based on their body weight during the 12-week open-label induction phase.

Guselkumab will be administered subcutaneously.

Autres noms:
  • CNTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Autres noms:
  • CNTO1959
  • TREMFYA
Expérimental: Double-blind maintenance phase: Guselkumab SC Dose Regimen 1

At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 1 SC based on their body weight up to Week 48.

Guselkumab will be administered subcutaneously.

Autres noms:
  • CNTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Autres noms:
  • CNTO1959
  • TREMFYA
Expérimental: Double-blind Maintenance Phase: Guselkumab SC Dose Regimen 2

At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 2 SC based on their body weight up to Week 48.

Guselkumab will be administered subcutaneously.

Autres noms:
  • CNTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Autres noms:
  • CNTO1959
  • TREMFYA
Expérimental: Open-label maintenance phase: Guselkumab SC

Week 12 non-responders will not be randomized and will enter an open-label maintenance phase to receive guselkumab SC dosing regimen based on their body weight up to Week 48.

Guselkumab will be administered subcutaneously.

Autres noms:
  • CNTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Autres noms:
  • CNTO1959
  • TREMFYA

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Percentage of Participants with Clinical Remission at Week 52
Délai: Week 52

Percentage of participants with clinical remission at Week 52 will be assessed. Clinical remission is defined as pediatric Crohn's Disease activity index (PCDAI) less than or equal to (<=) 10.

Week 52
Percentage of Participants Who Achieve Endoscopic Response at Week 52
Délai: Week 52

Percentage of participants who achieve endoscopic response at Week 52 will be assessed. Endoscopic response is defined as greater than or equal to (>=) 50 percent (%) reduction (global) and greater than (>) 50% reduction (U.S specific) from simplified endoscopic score-Crohn's Disease (SES-CD) score at baseline.

Week 52

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Percentage of Participants with Clinical Response at Week 12
Délai: Week 12

Percentage of participants with clinical response at Week 12 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30.

Week 12
Percentage of Participants with Clinical Response at Week 52
Délai: Week 52

Percentage of participants with clinical response at Week 52 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30.

Week 52
Percentage of Participants with Clinical Remission at Week 12
Délai: Week 12

Percentage of participants with clinical remission at Week 12 will be assessed. Clinical remission is defined as PCDAI score <=10.

Week 12
Percentage of Participants with Endoscopic Remission at Week 52
Délai: Week 52

Percentage of participants with endoscopic remission at Week 52 will be assessed. Endoscopic remission is defined as SES-CD total score <=4 and at least a 2-point reduction from baseline and no subscore >1.

Week 52
Percentage of Participants with Corticosteroid-free Remission at Week 52
Délai: Week 52

Percentage of participants with corticosteroid-free remission at Week 52 will be assessed. Corticosteroid-free remission is defined as PCDAI score <=10 at Week 52 and not receiving corticosteroids for at least 90 days before Week 52.

Week 52
Percentage of Participants with Sustained Clinical Remission at Weeks 12, 24, and 52
Délai: Weeks 12, 24, and 52

Percentage of participants with sustained clinical remission at Weeks 12, 24, and 52 will be assessed. Sustained clinical remission is defined as PCDAI <=10 at Weeks 12, 24, and 52.

Weeks 12, 24, and 52
Percentage of Participants with Clinical remission by Patient-Reported Outcome (PRO-2)
Délai: Week 12 and/or Week 52

Percentage of participants with clinical remission by PRO-2 will be assessed. Clinical remission by PRO-2 is defined as stool frequency (SF) <=3 and abdominal pain (AP) <=1 and no worsening of SF and AP from baseline.

Week 12 and/or Week 52
Serum Concentration of Guselkumab During Induction Phase
Délai: From Week 0 to Week 12

Serum concentrations of guselkumab will be assessed. Serum samples will be analyzed to determine concentrations of guselkumab using a validated, specific, and sensitive immunoassay method.

From Week 0 to Week 12
Trough Plasma Concentration (Ctrough) of Guselkumab During Maintenance Phase
Délai: At Weeks 16, 24, 36, 48 and 52

Ctrough is defined as the serum concentration of guselkumab immediately prior (pre-dose) to the next drug administration.

At Weeks 16, 24, 36, 48 and 52
Change from Baseline in Body Weight at Weeks 12, 24, and 52
Délai: Baseline, Weeks 12, 24, and 52

Change from baseline in body weight at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Body Weight Percentiles at Weeks 12, 24, and 52
Délai: Baseline, Weeks 12, 24, and 52

Change from baseline in body weight percentiles at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Body Weight z-scores at Weeks 12, 24, and 52
Délai: Baseline, Weeks 12, 24, and 52

Change from baseline in body weight z-scores at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Height at Weeks 12, 24, and 52
Délai: Baseline, Weeks 12, 24, and 52

Change from baseline in height at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Height Percentiles at Weeks 12, 24, and 52
Délai: Baseline, Weeks 12, 24, and 52

Change from baseline in height percentiles at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Height z-scores at Weeks 12, 24, and 52
Délai: Baseline, Weeks 12, 24, and 52

Change from baseline in height z-scores at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Height Velocity at Weeks 12, 24, and 52
Délai: Baseline, Weeks 12, 24, and 52

Change from baseline in height velocity at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Percentage of Participants with Clinical Remission
Délai: Week 52

Percentage of participants with clinical remission who were assigned to guselkumab dose regimen 1 and did not receive rescue therapy at Week 52 will be assessed. Clinical remission is defined as PCDAI score <=10.

Week 52
Percentage of Participants Who Achieve Endoscopic Response
Délai: Week 52

Percentage of participants who achieve endoscopic response who were assigned to q4w maintenance therapy and did not receive rescue therapy at Week 52 will be assessed. Endoscopic response is defined as >=50% reduction (global) and >50% reduction (U.S specific) from SES-CD score at baseline.

Week 52
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Délai: Up to Week 64

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. An SAE is is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important.

Up to Week 64

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Directeur d'études: Clinical Trial, Janssen Research & Development, LLC

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

13 mars 2024

Achèvement primaire (Estimé)

27 octobre 2027

Achèvement de l'étude (Estimé)

14 août 2028

Dates d'inscription aux études

Première soumission

20 juin 2023

Première soumission répondant aux critères de contrôle qualité

20 juin 2023

Première publication (Réel)

28 juin 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

3 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

2 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • CR109212
  • 2021-006282-37 (Numéro EudraCT)
  • CNTO1959PBCRD3007 (Autre identifiant: Janssen Research & Development, LLC)
  • 2023-504735-41-00 (Identificateur de registre: EUCT number)
  • 2023 (Subvention/contrat des NIH des États-Unis)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner